• Corpus ID: 228083978

Modeling Disease Progression Trajectories from Longitudinal Observational Data

  title={Modeling Disease Progression Trajectories from Longitudinal Observational Data},
  author={Bum Chul Kwon and Peter Achenbach and Jessica L. Dunne and William A. Hagopian and Markus Lundgren and Kenney Ng and Riitta Veijola and Brigitte I. Frohnert and Vibha Anand and the T1DI Study Group},
  journal={AMIA ... Annual Symposium proceedings. AMIA Symposium},
Analyzing disease progression patterns can provide useful insights into the disease processes of many chronic conditions. These analyses may help inform recruitment for prevention trials or the development and personalization of treatments for those affected. We learn disease progression patterns using Hidden Markov Models (HMM) and distill them into distinct trajectories using visualization methods. We apply it to the domain of Type 1 Diabetes (T1D) using large longitudinal observational data… 

Figures from this paper

User-driven Analysis of Longitudinal Health Data with Hidden Markov Models for Clinical Insights

This demo introduces an interactive visualization system called DPVis, which was designed to help researchers to interactively explore HMM outcomes and provides guidelines of how to implement the clinician-in-the-loop approach for analyzing longitudinal, observational health data with visual analytics.

Progression of type 1 diabetes from latency to symptomatic disease is predicted by distinct autoimmune trajectories

A model to predict and visualize progression to diabetes by using a large longitudinal data set on autoantibodies and clinical parameters as input is presented, showing that the health state of participants progresses from 11 distinct latent states as per three trajectories, enabling clinically useful prediction of disease onset.

Efficient Learning and Decoding of the Continuous-Time Hidden Markov Model for Disease Progression Modeling

This paper presents the first complete characterization of efficient EM-based learning methods for CT-HMM models, as well as the first solution to decoding the optimal state transition sequence and the corresponding state dwelling time.

Islet Autoantibody Type-Specific Titer Thresholds Improve Stratification of Risk of Progression to Type 1 Diabetes in Children.

This study defined islet autoantibody type-specific titer thresholds that significantly improved type 1 diabetes risk stratification in children and effectively identified children with a ≥50% 5-year risk when considering age-specific autoantIBody screening.



Disease Progression Modeling: Key Concepts and Recent Developments

An overview of key concepts in disease progression modeling is provided followed by illustrative examples from models for Alzheimer’s disease and recent novel applications in which disease progression models have been linked to cost-effectiveness analysis and genomic analysis are described.

A probabilistic disease progression modeling approach and its application to integrated Huntington’s disease observational data

A framework to build probabilistic disease progression models using observational medical data that addresses practical challenges in observational data and can help enhance the understanding of progression of chronic diseases.

Disease progression modeling using Hidden Markov Models

This study focuses on AD and shows that the proposed HMM model, when evaluated on the cross validation data, can identify more granular disease stages than the three currently accepted clinical stages of “Normal”, “MCI” (Mild Cognitive Impairment), and “AD”.

Multistate Markov models for disease progression with classification error

A general hidden Markov model for simultaneously estimating transition rates and probabilities of stage misclassification of chronic diseases, based on data from a trial of aortic aneurysm screening, in which the screening measurements are subject to error.

Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression

The results reveal that brain atrophy in the striatum and expansion of the ventricular system are highly predictive of the inflection points of the motor and cognitive function trajectories, and may be useful biomarkers as early signs of Huntington's Disease onset.

Unsupervised learning of disease progression models

A probabilistic disease progression model that learns a continuous-time progression model from discrete-time observations with non-equal intervals and learns a compact set of medical concepts as the bridge between the hidden progression process and the observed medical evidence, which are usually extremely sparse and noisy.

A novel approach for the analysis of longitudinal profiles reveals delayed progression to type 1 diabetes in a subgroup of multiple-islet-autoantibody-positive children

The novel clustering approach provides a tool for stratification of islet autoantibody-positive individuals that has prognostic relevance, and new opportunities in elucidating disease mechanisms.

Efficient Learning of Continuous-Time Hidden Markov Models for Disease Progression

This paper presents the first complete characterization of efficient EM-based learning methods for CT-HMM models and demonstrates the use of CT-HMMs with more than 100 states to visualize and predict disease progression using a glaucoma dataset and an Alzheimer's disease dataset.

Time-Resolved Autoantibody Profiling Facilitates Stratification of Preclinical Type 1 Diabetes in Children

A novel wavelet-based algorithm allows refined grouping of β-cell autoantibody–positive children who distinctly progressed to clinical type 1 diabetes, and it provides new opportunities in searching for etiological factors and elucidating complex disease mechanisms.

Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio.